{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:12:01Z","timestamp":1762603921427,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacpajpe.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Pharmaceutical Education"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.5688\/ajpe78355","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T21:31:37Z","timestamp":1397770297000},"page":"55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Application of Genomic Principles to Pharmacotherapy of Cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Christopher L.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy G.","family":"Pedigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy R.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.5688\/ajpe78355_bb0010","unstructured":"Accreditation Council for Pharmacy Education. Accreditation standards and guidelines for the professional program in pharmacy leading to the doctor of pharmacy degree. February 2006. https:\/\/www.acpe-accredit.org\/pdf\/ACPE_Revised_PharmD_Standards_Adopted_Jan152006.pdf. Accessed October 1, 2013."},{"issue":"3","key":"10.5688\/ajpe78355_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5688\/aj700360","article-title":"An assessment system for mapping CAPE outcomes in an advanced pharmacy practice experience program","volume":"70","author":"Turner","year":"2006","journal-title":"Am J Pharm Educ."},{"issue":"5797","key":"10.5688\/ajpe78355_bb0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"Sjoblom","year":"2006","journal-title":"Science."},{"issue":"5","key":"10.5688\/ajpe78355_bb0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.5688\/ajpe78355_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med."},{"issue":"5","key":"10.5688\/ajpe78355_bb0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","article-title":"Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy","volume":"94","author":"Herbst","year":"2002","journal-title":"Cancer."},{"issue":"1 Suppl 4","key":"10.5688\/ajpe78355_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/sonc.2002.31522","article-title":"Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment","volume":"29","author":"Lynch","year":"2002","journal-title":"Semin Oncol."},{"issue":"13","key":"10.5688\/ajpe78355_bb0045","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.5688\/ajpe78355_bb0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/cbt.25191","article-title":"Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer","volume":"14","author":"Al-Marrawi","year":"2013","journal-title":"Cancer Biol Ther."},{"issue":"19","key":"10.5688\/ajpe78355_bb0055","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"26","key":"10.5688\/ajpe78355_bb0060","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"10.5688\/ajpe78355_bb0065","unstructured":"Highlights of prescribing information for Erbitux (cetuximab). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125084s168lbl.pdf. Accessed October 1, 2013"},{"key":"10.5688\/ajpe78355_bb0070","unstructured":"Highlights of prescribing information for Vectibix (panitumumab). http:\/\/pi.amgen.com\/united_states\/vectibix\/vectibix_pi.pdf. Accessed October 1, 2013."},{"key":"10.5688\/ajpe78355_bb0075","unstructured":"Highlights of prescribing information for Zelboraf (vemurafenib). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202429s000lbl.pdf. Accessed October 1, 2013."},{"issue":"3","key":"10.5688\/ajpe78355_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5688\/ajpe75351","article-title":"Assessment of the pharmacogenomics educational needs of pharmacists","volume":"75","author":"McCullough","year":"2011","journal-title":"Am J Pharm Educ."},{"issue":"6892","key":"10.5688\/ajpe78355_bb0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"issue":"8","key":"10.5688\/ajpe78355_bb0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim Biophys Acta."},{"issue":"6","key":"10.5688\/ajpe78355_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell."},{"issue":"35","key":"10.5688\/ajpe78355_bb0100","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.5688\/ajpe78355_bb0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.5688\/ajpe78355_bb0110","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"Laurent-Puig","year":"2009","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.5688\/ajpe78355_bb0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res."},{"issue":"6","key":"10.5688\/ajpe78355_bb0120","doi-asserted-by":"crossref","first-page":"e21632","DOI":"10.1371\/journal.pone.0021632","article-title":"Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance","volume":"6","author":"Oikonomou","year":"2011","journal-title":"PloS One."},{"issue":"2","key":"10.5688\/ajpe78355_bb0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijc.2910410221","article-title":"Biological characterization and oncogene expression in human colorectal carcinoma cell lines","volume":"41","author":"Trainer","year":"1988","journal-title":"Int J Cancer. 15"},{"issue":"7391","key":"10.5688\/ajpe78355_bb0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature."},{"issue":"Database issue","key":"10.5688\/ajpe78355_bb0135","doi-asserted-by":"crossref","first-page":"D652","DOI":"10.1093\/nar\/gkp995","article-title":"COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer","volume":"38","author":"Forbes","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.5688\/ajpe78355_bb0140","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"10.5688\/ajpe78355_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-4608(94)00225-Z","article-title":"DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin","volume":"81","author":"Chen","year":"1995","journal-title":"Cancer Genet Cytogenet."},{"issue":"8","key":"10.5688\/ajpe78355_bb0150","first-page":"3790","article-title":"Dome formation by a human colonic adenocarcinoma cell line (HCA-7)","volume":"45","author":"Kirkland","year":"1985","journal-title":"Cancer Res."},{"issue":"1","key":"10.5688\/ajpe78355_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","article-title":"One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice","volume":"59","author":"Fogh","year":"1977","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"10.5688\/ajpe78355_bb0160","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mcp.2004.05.004","article-title":"Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E","volume":"18","author":"Jarry","year":"2004","journal-title":"Mol Cell Probes."},{"issue":"2 Pt 1","key":"10.5688\/ajpe78355_bb0165","first-page":"467","article-title":"Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line","volume":"36","author":"Drewinko","year":"1976","journal-title":"Cancer Res."},{"issue":"3","key":"10.5688\/ajpe78355_bb0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF02796440","article-title":"Human colonic adenocarcinoma cells. I. Establishment and description of a new line","volume":"12","author":"Tom","year":"1976","journal-title":"In Vitro."},{"issue":"8","key":"10.5688\/ajpe78355_bb0175","first-page":"2112","article-title":"Diverse cellular responses elicited from human colon carcinoma cells by transforming growth factor-beta","volume":"49","author":"Chakrabarty","year":"1989","journal-title":"Cancer Res. 15"},{"issue":"12","key":"10.5688\/ajpe78355_bb0180","first-page":"4562","article-title":"Classification of human colorectal adenocarcinoma cell lines","volume":"36","author":"Leibovitz","year":"1976","journal-title":"Cancer Res."},{"issue":"5","key":"10.5688\/ajpe78355_bb0185","first-page":"1751","article-title":"Heterogeneity of malignant cells from a human colonic carcinoma","volume":"41","author":"Brattain","year":"1981","journal-title":"Cancer Res."},{"issue":"2","key":"10.5688\/ajpe78355_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2353\/jmoldx.2009.080100","article-title":"Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors","volume":"11","author":"Pichler","year":"2009","journal-title":"J Mol Diagn."},{"issue":"7387","key":"10.5688\/ajpe78355_bb0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature."},{"issue":"6","key":"10.5688\/ajpe78355_bb0200","first-page":"125","article-title":"A required course in human genomics, pharmacogenomics, and bioinformatics","volume":"70","author":"Brazeau","year":"2006","journal-title":"Am J Pharm Educ."},{"issue":"2","key":"10.5688\/ajpe78355_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9459(24)08714-X","article-title":"Pharmacogenetics and pharmacogenomics instruction in colleges and schools of pharmacy in the United States","volume":"69","author":"Latif","year":"2005","journal-title":"Am J Pharm Educ."},{"issue":"Fall","key":"10.5688\/ajpe78355_bb0210","first-page":"1","article-title":"Pharmacogenomics in the professional pharmacy curriculum: Content, presentation and importance","volume":"2","author":"Zdanowicz","year":"2006","journal-title":"Int J Pharm Educ."},{"key":"10.5688\/ajpe78355_bb0215","unstructured":"National Coalition for Health Professional Education in Genetics. Core competencies for all health professionals. http:\/\/www.nchpeg.org\/index.php?option=com_content&view=article&id=237&Itemid=84. Accessed June 1, 2013."}],"container-title":["American Journal of Pharmaceutical Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002945923027614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002945923027614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5688\/ajpe78355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:50:34Z","timestamp":1757695834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002945923027614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0002945923027614"],"URL":"https:\/\/doi.org\/10.5688\/ajpe78355","relation":{},"ISSN":["0002-9459"],"issn-type":[{"type":"print","value":"0002-9459"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of Genomic Principles to Pharmacotherapy of Cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Pharmaceutical Education","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5688\/ajpe78355","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Association of Colleges of Pharmacy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"55"}}